Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Can AstraZeneca's Motavizumab Leapfrog Synagis? Advisory Committee Will Weigh In

This article was originally published in The Pink Sheet Daily

Executive Summary

Panel meeting on the respiratory syncytial virus product - which demonstrated non-inferiority, but not superiority, to Synagis - is set for June 2.

You may also be interested in...

AstraZeneca's MedImmune Comes Closer To Motavizumab Approval, And A Tight Grip On RSV Market

AstraZeneca's biologics unit MedImmune is continuing to solidify its domination of the market for products to prevent serious respiratory syncytial virus disease in high-risk infants with a formal reply to FDA's "complete response" letter for its investigational product motavizumab

Glaxo and Pfizer Form HIV Venture, But A Spin-Off Could Be In The Wings

In a bid to patch over their respective weaknesses in the HIV marketplace, GlaxoSmithKline and Pfizer announced April 16 they are forming a jointly owned company combining their portfolios of existing and developing drugs

AstraZeneca Accelerates Biologics Strategy With Acquisition Of MedImmune

Following the merger, valued at roughly $15.6 billion, 27 percent of AstraZeneca’s portfolio will be in biologics.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts